Nicholas  Augustinos net worth and biography

Nicholas Augustinos Biography and Net Worth

Director of DexCom

Nicholas (Nick) Augustinos has served on our Board since November 2009. Nick is the President & CEO of Aver, Inc. a company specializing in bundled payment and analytics solutions. Besides his role as President & CEO Nick serves on the Board of Directors of Aver, Inc. Prior to Aver, Inc., Nick was the Senior Vice President Health Information Services and Strategy at Cardinal Health. In January 2015, he was appointed to the Board of Directors of the California Health Care Foundation (CHCF). CHCF has as its mission to improve care for all Californians through innovations that improve quality, increase efficiency, and lower the cost of care. Prior to CHCF Nick served on the Board of Directors of the SCAN Foundation (June 2011 - December 2014), an organization dedicated to advancing the development of a sustainable continuum of quality care for seniors. Nick served on the Board of Directors of Audax Health, now Rally (March 2012 - February 2014), specializing in consumer engagement solutions. Rally is currently part of Optum, a UnitedHealth Group company. Nick brings 30 years of broad managerial, consulting and business development experience in the private and public sector. He has worked with a diverse range of leading healthcare delivery systems, healthcare insurers and government organizations globally.

Prior to Cardinal Health, Nick was the Senior Director for Global Healthcare Operations at Cisco Systems, leading the go to market strategy for healthcare focusing on public sector bringing business and technical expertise along with thought leadership towards in the areas of connected health, wellness and care delivery. Nick started his career at Cisco as the Senior Director for Global Healthcare Solutions of the Internet Business Solutions Group – the strategic consulting business unit of Cisco – he led among other initiatives the Cisco HealthPresence™ development, Cisco’s core care-at-a-distance platform.

Prior to Cisco, Nick was Partner and Senior Strategic Consulting Expert, Global Health Services, for CSC. Prior to joining CSC, he was Vice President, Care Data Exchange business unit for CareScience, leading product development and services in the clinical document sharing space. Nick was also Vice President for Healtheon/ WebMD, responsible for marketing and sales for the company’s products and services. Prior to that, he was with Deloitte Consulting and was instrumental in establishing the healthcare practice for Deloitte’s San Francisco office, managing numerous projects for payers, providers, and integrated delivery networks. He started his career in healthcare as Vice President, Administration, of CliniShare.

What is Nicholas Augustinos' net worth?

The estimated net worth of Nicholas Augustinos is at least $60,192.08 as of February 16th, 2021. Mr. Augustinos owns 806 shares of DexCom stock worth more than $60,192 as of November 14th. This net worth estimate does not reflect any other investments that Mr. Augustinos may own. Learn More about Nicholas Augustinos' net worth.

How do I contact Nicholas Augustinos?

The corporate mailing address for Mr. Augustinos and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Nicholas Augustinos' contact information.

Has Nicholas Augustinos been buying or selling shares of DexCom?

Nicholas Augustinos has not been actively trading shares of DexCom over the course of the past ninety days. Most recently, Nicholas Augustinos sold 2,500 shares of the business's stock in a transaction on Friday, October 29th. The shares were sold at an average price of $600.03, for a transaction totalling $1,500,075.00. Learn More on Nicholas Augustinos' trading history.

Who are DexCom's active insiders?

DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.

Are insiders buying or selling shares of DexCom?

During the last twelve months, insiders at the medical device company sold shares 29 times. They sold a total of 253,409 shares worth more than $33,229,896.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.

Information on this page was last updated on 9/9/2024.

Nicholas Augustinos Insider Trading History at DexCom

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/29/2021Sell2,500$600.03$1,500,075.00View SEC Filing Icon  
6/3/2021Sell806$366.99$295,793.94View SEC Filing Icon  
2/16/2021Sell1,875$412.03$772,556.25806View SEC Filing Icon  
1/6/2021Sell625$375.00$234,375.00806View SEC Filing Icon  
9/16/2020Sell1,875$399.78$749,587.50806View SEC Filing Icon  
6/15/2020Sell1,875$366.65$687,468.75806View SEC Filing Icon  
2/14/2020Sell1,812$283.80$514,245.60View SEC Filing Icon  
12/16/2019Sell1,812$206.14$373,525.68View SEC Filing Icon  
11/7/2019Sell1,208$185.29$223,830.32View SEC Filing Icon  
9/16/2019Sell1,208$145.49$175,751.92View SEC Filing Icon  
6/14/2019Sell1,208$146.32$176,754.56View SEC Filing Icon  
8/6/2018Sell12,300$121.33$1,492,359.00View SEC Filing Icon  
12/12/2013Sell11,321$34.40$389,442.4011,130View SEC Filing Icon  
12/10/2013Sell97,541$33.64$3,281,279.2422,451View SEC Filing Icon  
See Full Table

Nicholas Augustinos Buying and Selling Activity at DexCom

This chart shows Nicholas Augustinos's buying and selling at DexCom by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DexCom Company Overview

DexCom logo
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $74.68
Low: $71.75
High: $75.78

50 Day Range

MA: $69.77
Low: $65.68
High: $74.85

2 Week Range

Now: $74.68
Low: $62.34
High: $142.00

Volume

4,192,267 shs

Average Volume

3,919,698 shs

Market Capitalization

$29.17 billion

P/E Ratio

44.72

Dividend Yield

N/A

Beta

1.17